These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1793 related items for PubMed ID: 23753114

  • 1. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P, Polyzos NP, Alsbjerg B, Erb K, Mikkelsen AL, Elbaek HO, Papanikolaou EG, Andersen CY.
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [Abstract] [Full Text] [Related]

  • 2. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S, Blockeel C, Tremellen KP, Fleming R, Tournaye H, Humaidan P, Nelson SM.
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [Abstract] [Full Text] [Related]

  • 3. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A, Ata B, Polat M, Son WY, Yarali H, Dahan MH.
    Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
    [Abstract] [Full Text] [Related]

  • 4. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M, Bogstad J, Bryndorf T, Løssl K, Roskær J, Holland T, Prætorius L, Zedeler A, Nilas L, Pinborg A.
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [Abstract] [Full Text] [Related]

  • 5. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY, Elbaek HO, Alsbjerg B, Laursen RJ, Povlsen BB, Thomsen L, Humaidan P.
    Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
    [Abstract] [Full Text] [Related]

  • 6. Ovulation triggering with hCG alone, GnRH agonist alone or in combination? A randomized controlled trial in advanced-age women undergoing IVF/ICSI cycles.
    Zhou C, Yang X, Wang Y, Xi J, Pan H, Wang M, Zhou Y, Xiao Y.
    Hum Reprod; 2022 Jul 30; 37(8):1795-1805. PubMed ID: 35595223
    [Abstract] [Full Text] [Related]

  • 7. Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial.
    Elgindy EA, Sibai H, Mostafa MI, Gibreel A, Darwish E, Maghraby H.
    Hum Reprod; 2018 Jun 01; 33(6):1079-1086. PubMed ID: 29562260
    [Abstract] [Full Text] [Related]

  • 8. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
    Humaidan P, Van Vaerenbergh I, Bourgain C, Alsbjerg B, Blockeel C, Schuit F, Van Lommel L, Devroey P, Fatemi H.
    Hum Reprod; 2012 Nov 01; 27(11):3259-72. PubMed ID: 22930004
    [Abstract] [Full Text] [Related]

  • 9. Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol.
    Griesinger G, Verweij PJ, Gates D, Devroey P, Gordon K, Stegmann BJ, Tarlatzis BC.
    PLoS One; 2016 Nov 01; 11(3):e0149615. PubMed ID: 26950065
    [Abstract] [Full Text] [Related]

  • 10. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
    Orvieto R.
    J Ovarian Res; 2015 Nov 04; 8():69. PubMed ID: 26536862
    [Abstract] [Full Text] [Related]

  • 11. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
    Kolibianakis EM, Venetis CA, Bosdou JK, Zepiridis L, Chatzimeletiou K, Makedos A, Masouridou S, Triantafillidis S, Mitsoli A, Tarlatzis BC.
    Hum Reprod; 2015 Feb 04; 30(2):432-40. PubMed ID: 25492411
    [Abstract] [Full Text] [Related]

  • 12. GnRH agonist trigger with intensive luteal phase support vs. human chorionic gonadotropin trigger in high responders: an observational study reporting pregnancy outcomes and incidence of ovarian hyperstimulation syndrome.
    Christopoulos G, Vlismas A, Carby A, Lavery S, Trew G.
    Hum Fertil (Camb); 2016 Sep 04; 19(3):199-206. PubMed ID: 27662416
    [Abstract] [Full Text] [Related]

  • 13. Gonadotropin-releasing hormone agonist (GnRHa) trigger - State of the art.
    Dosouto C, Haahr T, Humaidan P.
    Reprod Biol; 2017 Mar 04; 17(1):1-8. PubMed ID: 28215488
    [Abstract] [Full Text] [Related]

  • 14. GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.
    O'Neill KE, Senapati S, Maina I, Gracia C, Dokras A.
    J Assist Reprod Genet; 2016 Sep 04; 33(9):1175-84. PubMed ID: 27349252
    [Abstract] [Full Text] [Related]

  • 15. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
    Anaya Y, Mata DA, Letourneau J, Cakmak H, Cedars MI, Rosen MP.
    J Assist Reprod Genet; 2018 Feb 04; 35(2):297-307. PubMed ID: 29086322
    [Abstract] [Full Text] [Related]

  • 16. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
    Lainas GT, Kolibianakis EM, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas TG, Tarlatzis BC.
    Hum Reprod; 2013 Jul 04; 28(7):1929-42. PubMed ID: 23624582
    [Abstract] [Full Text] [Related]

  • 17. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology.
    Youssef MA, Van der Veen F, Al-Inany HG, Mochtar MH, Griesinger G, Nagi Mohesen M, Aboulfoutouh I, van Wely M.
    Cochrane Database Syst Rev; 2014 Oct 31; 2014(10):CD008046. PubMed ID: 25358904
    [Abstract] [Full Text] [Related]

  • 18. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C.
    Fertil Steril; 2008 Jan 31; 89(1):84-91. PubMed ID: 17462639
    [Abstract] [Full Text] [Related]

  • 19. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
    Engmann LL, Maslow BS, Kaye LA, Griffin DW, DiLuigi AJ, Schmidt DW, Grow DR, Nulsen JC, Benadiva CA.
    J Ovarian Res; 2019 Jan 26; 12(1):8. PubMed ID: 30684970
    [Abstract] [Full Text] [Related]

  • 20. Reproductive Outcome After GnRH Agonist Triggering With Co-Administration of 1500 IU hCG on the Day of Oocyte Retrieval in High Responders: A Long-Term Retrospective Cohort Study.
    Abdulkhalikova D, Bokal EV, Stimpfel M, Ciglar P, Korosec S.
    Front Endocrinol (Lausanne); 2022 Jan 26; 13():826411. PubMed ID: 35464066
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 90.